Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models.

With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of cognitive impairment in patients with Alzheimer's Disease and related conditions.
Our name ‘Syndesi’ comes from the Greek for ‘connection’. We are harnessing science to improve connections on many levels.

Syndesi Therapeutics is developing molecules which act in a unique way on the synaptic vesicle protein SV2A. SV2A plays a central role in synaptic transmission (connections between neurons).  Regulating the synaptic transmission is a promising approach to treat Alzheimer’s disease and other disorders with cognitive impairment.